PDS Biotechnology Corp (EU6)

11.540
-0.425(-3.55%)
  • Volume:
    0
  • Bid/Ask:
    0.000/0.000
  • Day's Range:
    11.540 - 11.620
  • Type:Equity
  • Market:Germany
  • ISIN:US70465T1079
  • WKN:A2PF3F

EU6 Overview

Prev. Close
11.965
Day's Range
11.54-11.62
Revenue
-
Open
11.62
52 wk Range
1.52-14.485
EPS
-26.25
Volume
0
Market Cap
302.12M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
167
P/E Ratio
-
Beta
3.7
1-Year Change
513.83%
Shares Outstanding
28,423,849
Next Earnings Date
Nov 10, 2021
What is your sentiment on PDS Biotechnology Corp?
or
Market is currently closed. Voting is open during market hours.

PDS Biotechnology Corp News

PDS Biotechnology Corp Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellSellSellSellNeutral
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Buy
SummaryStrong SellStrong SellStrong SellStrong SellBuy

PDS Biotechnology Corp Company Profile

PDS Biotechnology Corp Company Profile

Employees
15

PDS Biotechnology Corp, formerly Edge Therapeutics, Inc., is an immuno-oncology company, The Company is focused on developing a pipeline of clinical-stage immunotherapies. Its therapies are developed for the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Versamune is its synthetic lipid-based immunotherapy platform. Its lead product candidate, PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. Its pipeline also includes PDS0102, PDS0103 and PDS0104. Its pipeline of Versamune-based products are all administered by subcutaneous injection .DS0102 is being developed for the treatment of prostate and breast cancers. PDS0103 is based on novel agonist antigens of the mucin-1 (MUC-1) oncogenic C-terminal region. PDS0104 is being developed for the treatment of melanoma.

Read More
  • Researchers in Brazil warn that corona recoverers may re-infect the Brazilian variant. According to the study, the antibodies in the blood of recoverers infected with previous corona strains had a 6-fold reduced ability to neutralize the Brazilian strain.
    1
    • This company has little open news, do you know what they have in the pipe-line?
      0
      • It's back! This is going to the moon and beyond soon. Get in while you can.
        0
        • You better have a great earnings report. Real shady offering your stock at a lower price than listed. I'd sell immediately if I wouldn't lose so much money right now.
          0
          • Well ***happened today? It's up when the market is down and down when the market is up
            0
            • Got in at 4.24 today. Has potential to shoot high. Going to be a long term hold hopefully with steady growth.
              0
              • Anyone who is experienced have any thoughts for PDSB next week? Im in at 3.86
                0
                • I'm ready for the $2.00 movement!
                  0
                  • Finally some movement.. Lets go $2
                    0
                    • Yea! Hoping for $2 I have 2K shares
                      0
                      • Lol
                        1
                    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.